Physician profile
Jennifer E Winter
NPI 1740280056
$5,107.91
in general payments reported to CMS, 2019-2025
22 companies · $2,660 in 2025
The $2,660 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $312 · 2023: $672 · 2024: $1,241 · 2025: $2,660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,970 · Travel and Lodging: $488 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,970.02 |
| Travel and Lodging | $488.40 |
| Education | $115.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,326.39 | 2021-2025 | Tremfya |
| Arthrex, INC. | $632.40 | 2025 | |
| Abbvie INC. | $582.60 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $443.24 | 2023-2024 | Sotyktu |
| Pfizer INC. | $259.53 | 2022-2025 | |
| Ucb, INC. | $252.75 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $235.24 | 2022-2025 | Taltz, Ebglyss, Olumiant |
| Organon LLC | $172.78 | 2025 | Hadlima, Vtama |
| Sun Pharmaceutical Industries INC. | $155.64 | 2023-2025 | Winlevi |
| Dermavant Sciences, INC. | $140.34 | 2023 | Vtama |
| Arcutis Biotherapeutics, INC. | $131.04 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $125.81 | 2023-2025 | |
| Amgen INC. | $123.32 | 2021-2025 | Otezla, Otezla |
| Galderma Laboratories, L.P. | $121.35 | 2025 | Nemluvio |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.96 | 2025 | Siliq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $61.58 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $54.52 | 2025 | Libtayo |
| Incyte Corporation | $50.98 | 2025 | Opzelura |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.02 | 2025 | Spevigo |
| Genzyme Corporation | $37.54 | 2025 | |
| Leo Pharma INC. | $28.13 | 2025 | Anzupgo |
| Fidia Pharma USA INC. | $14.75 | 2025 | Triluron, Hymovis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Winter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.